Latest News
Ford Shares Flat as Canadian Labor Talks Begin; Inventory Poses Pricing Risk
Ford shares hover around $14 as Unifor begins Canadian labor negotiations, while elevated F-Series inventory raises potential pricing concerns.
Lumentum Rides AI Optical Demand to 6% Gain Despite Nasdaq Weakness
Lumentum shares surged 6.1% to $901.89, driven by a $400M+ optical circuit switch backlog and underappreciated co-packaged optics attach-rate upside, as AI infrastructure stocks attracted buyers.
Applied Optoelectronics Jumps on China Credit Line Expansion
Applied Optoelectronics shares surged 7.8% as a China unit doubled a credit line to RMB 500 million, indicating funding for AI optics production ramp.
Palantir Hits 52-Week Low as AI Hype Fades, Valuation Under Scrutiny
Palantir Technologies fell over 6% to a 52-week low of $119.76 as AI software valuations come under pressure, despite strong U.S. revenue growth and a raised 2026 outlook.
SoFi Shares Dip 3.6% as CEO's Buying Average and Funding Costs Take Center Stage
SoFi Technologies (SOFI) shares slid 3.6% to $17.26, nearly matching CEO Anthony Noto's 2026 open-market buying average, as investors weighed insider buying and deposit funding strength.
Rocket Lab Drops 7% on Nasdaq-100 Debut Amid Dilution Fears and Space Selloff
Rocket Lab shares dropped 7.2% to $99.49 on its Nasdaq-100 debut, pressured by a $3 billion at-the-market stock sale program and a broader space sector decline.
Student Loan Autopay Discount Slashed Ahead of July Reset
Eligible federal Direct Loan borrowers will receive a temporary 1-point interest rate cut through autopay from July 1, 2026, to June 30, 2028, as new loan rates increase to between 6.52% and 9.07%.
Oaktree-Backed ITG Targets $2.67B Valuation in Nasdaq IPO
ITG seeks up to $2.67 billion valuation in Nasdaq IPO, with most proceeds going to debt repayment. High customer concentration and cancellable backlog are key investor concerns.
AbbVie Acquires Apogee Therapeutics for $10.9B in Cash, Bolstering Pipeline
AbbVie announced a $10.9 billion cash acquisition of Apogee Therapeutics, adding a promising eczema treatment to its pipeline as it seeks to offset declining Humira sales.